Alexza Pharmaceuticals, Inc.
 (ALXA)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Nov. 5, 2015, 5:00 PM
    • Alexza Pharma (NASDAQ:ALXA): Q3 EPS of -$0.27 beats by $0.07.
    • Revenue of $1.8M (+291.3% Y/Y) beats by $0.2M.
    | Nov. 5, 2015, 5:00 PM
  • Aug. 6, 2015, 4:36 PM
    • Alexza Pharma (NASDAQ:ALXA): Q2 EPS of -$0.63 misses by $0.03.
    • Revenue of $1.88M (+27.0% Y/Y) beats by $0.39M.
    | Aug. 6, 2015, 4:36 PM
  • May 6, 2015, 4:49 PM
    • Alexza Pharma (NASDAQ:ALXA): Q1 EPS of -$0.02 may not be comparable to consensus of -$0.51.
    • Revenue of $0.7M (-67.7% Y/Y) misses by $2.66M.
    | May 6, 2015, 4:49 PM
  • Mar. 10, 2015, 9:28 AM
    • Alexza Pharmaceuticals (ALXA -3%) Q4 results: Revenues: $1.5M (+15.4%); COGS: $4M (-7.0%); R&D Expense: $3.2M (+23.1%); SG&A: $1.6M (-57.9%); Operating Loss: ($7.3M) (+22.3%); Net Loss: ($6.7M) (-17.5%); Loss Per Share: ($0.35) (-6.1%).
    • FY2014 results: Revenues: $5.6M (-88.3%); COGS: $15.9M (+42.0%); R&D Expense: $13.7M (-28.3%); SG&A: $13.3M (-15.8%); Operating Loss: ($37.5M) (-999%); Net Loss: ($36.7M) (+7.3%); Loss Per Share: ($2.07) (+13.0%); Quick Assets: $34.8M (+34.4%).
    • No guidance given.
    | Mar. 10, 2015, 9:28 AM
  • Mar. 9, 2015, 4:13 PM
    • Alexza Pharma (NASDAQ:ALXA): Q4 EPS of -$0.35 beats by $0.33.
    • Revenue of $1.45M (+10.7% Y/Y) misses by $1.54M.
    | Mar. 9, 2015, 4:13 PM
  • Nov. 5, 2014, 4:44 PM
    • Alexza Pharma (NASDAQ:ALXA): Q3 EPS of -$0.77 misses by $0.03.
    • Revenue of $0.5M (-77.0% Y/Y) misses by $1.23M.
    | Nov. 5, 2014, 4:44 PM
  • Oct. 8, 2014, 10:12 AM
    • Alexza Pharmaceuticals (ALXA -2.6%) will report Q3 results on November 5 after the close. The conference call will begin at 5:00 m ET.
    • Consensus view is a loss of ($0.77) per share on revenues of $3.2M.
    | Oct. 8, 2014, 10:12 AM
  • Aug. 8, 2014, 10:15 AM
    • Alexza Pharmaceuticals (ALXA -21.8%) Q2 results: Revenues: $1.5M (-96.6%); Operating Expenses: $12.8M (+2.1%); Operating Loss: ($11.3M) (-136.5%); Net Loss: ($6.0M) (-646.2%); Loss Per Share: ($0.34) (-580.0%); Quick Assets: $43.6M (+68.3%).
    • No guidance given.
    | Aug. 8, 2014, 10:15 AM
  • Aug. 7, 2014, 4:47 PM
    • Alexza Pharma (NASDAQ:ALXA): Q2 EPS of -$0.34 beats by $0.33.
    • Revenue of $1.48M (-96.6% Y/Y) misses by $0.76M.
    • Shares -2%.
    | Aug. 7, 2014, 4:47 PM
  • May 5, 2014, 6:49 PM
    • Alexza Pharmaceuticals (ALXA): Q1 EPS of -$0.62 beats by $0.02.
    • Revenue of $2.16M (+197% Y/Y) beats by $0.24M.
    | May 5, 2014, 6:49 PM
  • Mar. 6, 2014, 5:08 PM
    • Alexza Pharmaceuticals, Inc. (ALXA): Q4 EPS of -$0.33 beats by $0.43.
    • Revenue of $1.3M beats by $0.18M.
    | Mar. 6, 2014, 5:08 PM
  • Nov. 6, 2013, 6:51 PM
    • Alexza Pharmaceuticals, Inc. (ALXA): Q3 EPS of -$0.72 misses by $0.18.
    • Revenue of $$2.2M beats by $0.22M. (PR)
    | Nov. 6, 2013, 6:51 PM
  • Aug. 9, 2013, 8:50 AM
    • Alexza Pharmaceuticals (ALXA): Q2 EPS of -$0.21 may not be comparable to consensus of $0.09.
    • Revenue of $40.8M may not be comparable to consensus of $14.17M. (PR)
    | Aug. 9, 2013, 8:50 AM
  • May 15, 2013, 6:32 AM
    Alexza Pharmaceuticals (ALXA): Q1 EPS of -$1.31 misses by $0.86. Revenue of $729K beats by $271M. (PR)
    | May 15, 2013, 6:32 AM
  • Mar. 26, 2013, 5:44 PM

    More on Alexza Pharmaceuticals (ALXA): Q4 EPS misses expectations, with revenues coming at $729K, well below estimates of $3.48M. In the same period last year, the company reported a loss per share of $1.34 on revenues of $1.88M. R&D expenses were lower for the quarter, largely as a result of the suspension of development of AZ-007 and Staccato nicotine product candidates starting in late 2011, as well as efforts to conserve cash.

    | Mar. 26, 2013, 5:44 PM
Company Description
Alexza Pharmaceuticals Inc is a pharmaceutical company engaged in the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Its product includes ADASUVE.